BofA initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $38 price target WVE-007 in obesity is a key value driver, accounting for 56% of the firm’s price target says the analyst, who thinks WVE-007 could be differentiated in body composition. The firm models above-Street peak sales estimates of greater than $11B unadjusted, the analyst noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences participates in a conference call with Cantor
- Wave Life Sciences: Regained WVE-006 Rights and De-Risked Regulatory Pathway Drive Compelling Buy-Rated AATD Opportunity
- Wave Life Sciences price target raised to $43 from $40 at Canaccord
- Wave Life Sciences: Regained WVE-006 Ownership and Platform Validation Support Buy Rating and $33 Target
- Wave Life Sciences price target raised to $50 from $47 at Clear Street